Immunotherapy for Renal Medullary Carcinoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing if a combination of two drugs, nivolumab and relatlimab, can help control a type of kidney cancer called renal medullary carcinoma that has spread or is hard to treat. These drugs work by helping the immune system recognize and attack cancer cells. The goal is to improve treatment outcomes. Nivolumab has been approved for the treatment of various cancers, including renal cell carcinoma, and is often used in combination therapies.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot be on any anticancer therapies or high-dose steroids when starting the trial. It's best to discuss your specific medications with the trial team.
What safety data exists for immunotherapy treatments like Nivolumab and Relatlimab in humans?
Nivolumab, an immunotherapy treatment, has been used in patients with advanced kidney cancer and has shown some immune-related side effects like joint pain, muscle inflammation, and lung issues. However, many patients have experienced long-term benefits even after stopping treatment due to these side effects.12345
How is the drug Nivolumab, Relatlimab unique for treating Renal Medullary Carcinoma?
Nivolumab and Relatlimab are unique because they are immune checkpoint inhibitors that help the immune system recognize and attack cancer cells, which is different from traditional treatments that target blood vessel growth or cancer cell growth pathways. This approach is particularly novel for Renal Medullary Carcinoma, a rare cancer with limited standard treatment options.678910
What data supports the effectiveness of the drug Nivolumab for treating renal medullary carcinoma?
Who Is on the Research Team?
Pavlos Msaouel
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
Adults with advanced or metastatic renal medullary carcinoma (RMC), who may or may not have had a kidney removed, and are not currently pregnant or breastfeeding. Participants need to have proper organ function, can be treatment-naïve or previously treated for RMC, and must agree to use effective contraception. Those with controlled brain metastases post-treatment are eligible; however, individuals with severe medical conditions, other recent cancers, HIV/AIDS, uncontrolled brain metastases, active myocarditis or hepatitis B/C infection cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive nivolumab 480 mg IV plus relatlimab 480 mg IV every 4 weeks for up to 2 years
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nivolumab
- Relatlimab
Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor